Acquisition binges often lead to hangovers; here’s what to watch out for.
More efforts are needed to raise awareness of biosimilars among physicians and patients in Europe and address scepticisms about the quality and safety of biosimilars.
FDA and bio/pharma companies get serious about continuous manufacturing to ensure product quality.
Uncertainty about the demand for a biologic medication can be partly mollified with some well-planned capacity outsourcing, contends a new report by ORC International sponsored by Patheon.
The new company is the product of a merger with Formex.
BioPharm sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.
The agency publishes draft reference material for implementation of FDA’s quality metrics guidance.
The agency has suspended recommendation of Riluzole Alkem due to flawed study results.
The agency is following up on a February 2016 inspection of the facility that found GMP violations.